This is currently being investigated in patients with multiple system atrophy, another synucleinopathy, in an on-going Phase 2 trial of MEDI1341 (ClinTrials.gov ID: NCT05526391), which aims to evaluate whether a reduction in free α-synuclein in human CSF translates into slowing of disease progression. Here, SNCA is linked to synucleinopathy.